Taylor v. Wexford Health Sources, Incorporated

District Court, S.D. West Virginia·Decided June 17, 2024·No. 2:23-cv-00475·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA

CHARLESTON DIVISION

JOSEPH TAYLOR,

Plaintiff,

v. CIVIL ACTION NO. 2:23-cv-00475

WEXFORD HEALTH SOURCES, INCORPORATED, et al.,

Defendants.

MEMORANDUM OPINION AND ORDER

The Court has reviewed the Plaintiff’s Motion to Exclude Certain Opinions of Dr. Grady Bazzel (Document 220) and the Defendants’ Joint Response in Opposition to Exclude Certain Opinions of Dr. Grady Bazzel (Document 226), as well as all attached exhibits.1 Dr. Grady J. Bazzel submitted an expert report in this matter dated February 13, 2024. (Bazzel Rep.) (Document 202-8.) He indicates that his opinions are based on his “training, education, and experience, as well as a review of the medical records and other documents/information in this case.” (Id. at 1.) Dr. Bazzel is currently the Patient Safety Officer and Medical Director of Care Management for Wellpath, a company that provides correctional healthcare throughout the United States. He has worked in corrections since 2005 and is licensed to practice medicine in multiple states. In his current role, he investigates patient deaths and other care errors and helps improve quality of care across Wellpath-managed sites. He has familiarity

1 For ease of reference, the Court has cited to the deposition and report submitted with the dispositive motions briefing. with the Bureau of Prisons (BOP) Clinical Guidelines for the Diagnosis, Evaluation, and Treatment of Opioid Use Disorder (OUD), although he did not review them specifically while compiling his report. (Bazzel Dep. at 74-75) (Document 195-7.) Dr. Bazzel has some experience treating patients going through withdrawal, but limited experience prescribing Medications for Opioid Use Disorder (MOUD). He obtained a DEA X-waiver, which was then necessary to prescribe

buprenorphine, in 2011, but did not use it and did not retain it after 2013. (Id. at 48-49.) He again obtained the X-waiver in 2020 and prescribed buprenorphine to continue the medication for some patients who entered custody with active prescriptions, although he has never conducted a screening for OUD. (Id. at 47-57.) He has not prescribed MOUD since 2020, and he has never induced a patient onto buprenorphine. (Id. at 220-221.) In his report, Dr. Bazzel outlines Mr. Taylor’s medical records from his incarceration at Central Regional Jail (CRJ) beginning on January 1, 2023. The report notes that Mr. Taylor reported his use of Suboxone to treat OUD to intake staff, and that his urine drug screen on intake was positive for methamphetamine, amphetamine, and fentanyl, and negative for buprenorphine.

It notes that he was prescribed various medications to treat withdrawal symptoms and opines that his COWS scores “reflected either no or mild withdrawal,” with two COWS scores showing moderate withdrawal. (Bazzel Rep. at 3.) The report recounts that “Mr. Taylor actively refused to participate in this process on at least one occasion on the following days: January 2, 6, 7, 8, and 11, 2023.” (Id. at 4.) Dr. Bazzel explains that there are risks to the use of MOUD in correctional settings that are not present in the outside world, including the risk that other inmates will target a patient to obtain the medication.

2 Dr. Bazzel states that “[p]roper patient selection is the key to a successful Medication Assisted Treatment (MAT) program.” (Id.) He states that the “psychological triggers for relapse are less present and the access to substances of abuse is greatly diminished,” during incarceration, reducing the need for treatment. (Id.) Dr. Bazzel suggests that gaps in Mr. Taylor’s treatment record, both before and after his period of incarceration, show a “pattern of spotty follow-up for

this medication that he claims to need so badly,” and that combined with reduced triggers for craving/relapse and decreased access to opioids in jail, supports having “him undergo a medically supervised withdrawal and see[ing] what degree of severity his OUD is under monitored circumstances.” (Id. at 5.) Dr. Bazzel opines that urine drug screens “should play into medical decision making in this type of situation,” and notes that Mr. Taylor had periods in which he submitted drug tests that were negative for all substances, indicating that he “was able to abstain from the use of opioids…without buprenorphine or he used opioids during a timeframe where they would not show up on the urine drug screen.” (Id.) He also notes a post-incarceration drug screen that was positive for buprenorphine and fentanyl, which he suggests demonstrates that the

buprenorphine was ineffective. (Id.) Dr. Bazzel states that he has “treated literally thousands of patients” with medically supervised withdrawal from opioids “with no negative outcomes.” (Id.) He offers the opinion that Mr. Taylor was not a good candidate for MAT while incarcerated because of his lack of compliance with COWS assessments, his urine drug screen results, and his gaps in treatment before and after his incarceration. He further opines that “the medical staff at CRJ were under no obligation to continue [buprenorphine] until such time that it became clear that it was needed. This need never presented itself,” as demonstrated by “the fact that his first drug screen post-

3 incarceration was negative for illicit drugs.” (Id. at 6.) He indicates that his disagreement with the opinions expressed by the Plaintiff’s expert is based on the fact that Mr. Taylor did not present as “an established patient who had been compliant for an extended period of time with his treatment with buprenorphine.” (Id.) He disputes the Plaintiff’s allegations that Wexford has a policy or practice of denying MOUD. Finally, he states that he “will testify that the defendants

met the standard of care in their treatment of Mr. Taylor,” that he sees “no evidence of medical malpractice, deliberate indifference, discrimination (due to his OUD or any other reason), or negligence by any of the defendants,” and that “[n]o errors of omission or commission on the part of the defendants led to any harm (lasting or otherwise) to this patient.” (Id.) ARGUMENT

The Plaintiff argues that the opinions in Dr. Bazzel’s report are contradicted by both the record and his own deposition testimony in several respects, including with regard to the existence of a policy or practice of forced withdrawal for OUD patients without an active MOUD prescription. He argues that Dr. Bazzel lacks experience and specialized training related to OUD, MOUD, and opioid withdrawal, and admitted that his opinions were not supported by published medical or scientific reports. The Plaintiff notes that Dr. Bazzel has “never conducted an OUD screening or a Rapid Opioid Dependence Screen and is not sure if he has ever reviewed such a test.” (Pl.’s Mot. at 8.) The Plaintiff further contends that Dr. Bazzel’s opinions are contradicted in key areas by the BOP Guidelines, a resource that he stated he was familiar with and considered

authoritative. He urges the Court to exclude Dr. Bazzel as an expert entirely. Absent full exclusion, the Plaintiff argues that several specific opinions offered by Dr. Bazzel are improper. He argues that Dr. Bazzel should not be permitted to offer opinions on the 4 legal issues of medical malpractice, deliberate indifference, discrimination, and negligence. In addition, he contends that Dr. Bazzel’s opinion on the reduction in psychological triggers in jails and prisons should be excluded because it lacks any scientific support, and he is not a psychiatrist or psychologist with any qualification to offer such testimony. The Plaintiff next argues that Dr. Bazzel’s testimony and conclusions related to incidents of alleged diversion and urine screen

Free access — add to your briefcase to read the full text and ask questions with AI

Taylor v. Wexford Health Sources, Incorporated, (S.D.W. Va. 2024).

Taylor v. Wexford Health Sources, Incorporated (Taylor v. Wexford Health Sources, Incorporated) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
United States v. Robert Melvin Harris
995 F.2d 532 (Fourth Circuit, 1993)
Creekmore v. Maryview Hospital
662 F.3d 686 (Fourth Circuit, 2011)
Oglesby v. General Motors Corp.
190 F.3d 244 (Fourth Circuit, 1999)
Cooper v. Smith & Nephew, Inc.
259 F.3d 194 (Fourth Circuit, 2001)
Howard Nease v. Ford Motor Company
848 F.3d 219 (Fourth Circuit, 2017)
Westberry v. Gislaved Gummi AB
178 F.3d 257 (Fourth Circuit, 1999)
Kopf v. Skyrm
993 F.2d 374 (Fourth Circuit, 1993)